Impact of ixazomib‐lenalidomide‐dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging‐markets subgroup of the TOURMALINE‐MM1 trial

Abstract Ixazomib‐lenalidomide‐dexamethasone (ixazomib‐Rd) showed clinical efficacy over placebo‐Rd in patients with relapsed/refractory multiple myeloma (MM) in the TOURMALINE‐MM1 trial. Over a median follow‐up of ∼85 months, as patients showed disease progression, they received subsequent novel th...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Andrew Spencer, Olga Samoilova, Wee‐Joo Chng, Richard Labotka, Cong Li, Kwang‐Wei Wu, Nakul Saxena, Xu Yan, Jae Hoon Lee, Meral Beksac
Format:	Artigo
Jezik:	Inglês
Izdano:	Wiley 2022-11-01
Serija:	eJHaem
Teme:	emerging‐markets ixazomib multiple myeloma overall survival proteasome inhibitor
Online dostop:	https://doi.org/10.1002/jha2.548
Oznake:	Označite Brez oznak, prvi označite!